• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

乳糜泻及小肠免疫介导性疾病中的肝脏受累情况

Liver Involvement in Celiac Disease and Immune-Mediated Diseases of the Small Bowel.

作者信息

Nandi Nicoletta, Verdu Elena F, Schuppan Detlef, Gomez-Aldana Andres Jose, Pinto-Sanchez Maria Ines, Conforti Francesco Simone, Maggioni Marco, Caprioli Flavio, Elli Luca

机构信息

Gastroenterology and Endoscopy Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milano, Italy.

Department of Pathophysiology and Transplantation, Università degli Studi di Milano, Milano, Italy.

出版信息

Liver Int. 2025 Aug;45(8):e70206. doi: 10.1111/liv.70206.

DOI:10.1111/liv.70206
PMID:40679061
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12272813/
Abstract

Disorders of the hepatobiliary system are commonly associated with gastrointestinal (GI) diseases. The GI and hepatobiliary systems interact through the portal vein system and enterohepatic circulation, creating a gut-liver axis that allows for a complex multidirectional interplay between immune, hormonal, dietary and environmental luminal factors that include the gut microbiota. This interaction may underlie the liver affection in autoimmune and immune-mediated small bowel diseases through a variety of pathways that include autoimmune, metabolic, immune-mediated, and/or iatrogenic mechanisms. Despite evidence of a gut-liver axis and co-morbid liver associations with small bowel diseases, the clinical implications and how these conditions should be clinically managed remain unclear. In this narrative review, we describe the hepato-biliary manifestations associated with chronic immune-mediated enteropathies of the small bowel in adults, with particular focus on CeD and Crohn's disease.

摘要

肝胆系统疾病通常与胃肠道(GI)疾病相关。胃肠道和肝胆系统通过门静脉系统和肠肝循环相互作用,形成了一个肠-肝轴,使得免疫、激素、饮食和环境腔道因素(包括肠道微生物群)之间能够进行复杂的多向相互作用。这种相互作用可能通过多种途径,包括自身免疫、代谢、免疫介导和/或医源性机制,成为自身免疫性和免疫介导的小肠疾病中肝脏受累的基础。尽管有证据表明存在肠-肝轴以及肝脏与小肠疾病的共病关联,但临床意义以及这些疾病应如何进行临床管理仍不明确。在这篇叙述性综述中,我们描述了与成人慢性免疫介导的小肠病相关的肝胆表现,特别关注乳糜泻(CeD)和克罗恩病。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c466/12272813/b0fa3b9aeb5b/LIV-45-0-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c466/12272813/b0fa3b9aeb5b/LIV-45-0-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c466/12272813/b0fa3b9aeb5b/LIV-45-0-g001.jpg

相似文献

1
Liver Involvement in Celiac Disease and Immune-Mediated Diseases of the Small Bowel.乳糜泻及小肠免疫介导性疾病中的肝脏受累情况
Liver Int. 2025 Aug;45(8):e70206. doi: 10.1111/liv.70206.
2
Clinical Practice Updates: AGA Clinical Practice Update on GI Manifestations and Autonomic or Immune Dysfunction in Hypermobile Ehlers-Danlos Syndrome: Expert Review.临床实践更新:美国胃肠病学会关于可弯曲性埃勒斯-当洛综合征的胃肠道表现及自主神经或免疫功能障碍的临床实践更新:专家综述
Clin Gastroenterol Hepatol. 2025 May 19. doi: 10.1016/j.cgh.2025.02.015.
3
Interventions for the management of abdominal pain in Crohn's disease and inflammatory bowel disease.干预措施用于克罗恩病和炎症性肠病的腹痛管理。
Cochrane Database Syst Rev. 2021 Nov 29;11(11):CD013531. doi: 10.1002/14651858.CD013531.pub2.
4
LINE-1 hypomethylation characterizes the inflammatory response in coeliac disease associated-intestinal mucosa and small bowel adenocarcinomas.LINE-1低甲基化是乳糜泻相关肠黏膜和小肠腺癌炎症反应的特征。
J Pathol. 2025 Jan;265(1):99-109. doi: 10.1002/path.6371. Epub 2024 Nov 27.
5
Diagnostic Challenges in Enteropathies: A Histopathological Review.肠病的诊断挑战:组织病理学综述
Diagnostics (Basel). 2025 Jun 13;15(12):1511. doi: 10.3390/diagnostics15121511.
6
Natalizumab for induction of remission in Crohn's disease.那他珠单抗用于诱导克罗恩病缓解
Cochrane Database Syst Rev. 2006 Jul 19(3):CD006097. doi: 10.1002/14651858.CD006097.
7
Synbiotics, prebiotics and probiotics for solid organ transplant recipients.固体器官移植受者的共生元、益生元和益生菌。
Cochrane Database Syst Rev. 2022 Sep 20;9(9):CD014804. doi: 10.1002/14651858.CD014804.pub2.
8
Integrating Gut Microbiome and Metabolomics with Magnetic Resonance Enterography to Advance Bowel Damage Prediction in Crohn's Disease.整合肠道微生物组和代谢组学与磁共振肠造影术以推进克罗恩病肠道损伤预测
J Inflamm Res. 2025 Jun 11;18:7631-7649. doi: 10.2147/JIR.S524671. eCollection 2025.
9
Natalizumab for induction of remission in Crohn's disease.那他珠单抗用于诱导克罗恩病缓解
Cochrane Database Syst Rev. 2007 Jan 24(1):CD006097. doi: 10.1002/14651858.CD006097.pub2.
10
Stem cell transplantation for induction of remission in medically refractory Crohn's disease.干细胞移植治疗药物难治性克罗恩病诱导缓解。
Cochrane Database Syst Rev. 2022 May 13;5(5):CD013070. doi: 10.1002/14651858.CD013070.pub2.

本文引用的文献

1
Non-invasive assessment of portal hypertension: Liver stiffness and beyond.门静脉高压的非侵入性评估:肝脏硬度及其他方面。
JHEP Rep. 2024 Dec 11;7(3):101300. doi: 10.1016/j.jhepr.2024.101300. eCollection 2025 Mar.
2
Extraintestinal complications of celiac disease: treatment considerations.乳糜泻的肠外并发症:治疗考量
Expert Rev Gastroenterol Hepatol. 2024 Dec;18(12):761-777. doi: 10.1080/17474124.2024.2443053. Epub 2024 Dec 25.
3
Porto-sinusoidal vascular liver disorder with portal hypertension: Natural history and long-term outcome.
伴有门静脉高压的肝门-肝窦状隙血管疾病:自然病程与长期预后
J Hepatol. 2025 Jan;82(1):72-83. doi: 10.1016/j.jhep.2024.07.035. Epub 2024 Aug 22.
4
Inflammatory Bowel Disease Therapies and Acute Liver Injury.炎症性肠病治疗与急性肝损伤
Toxics. 2024 Jun 8;12(6):421. doi: 10.3390/toxics12060421.
5
Liver manifestation of patients with celiac disease: A single center experience.腹腔疾病患者的肝脏表现:单中心经验。
Ann Diagn Pathol. 2024 Aug;71:152327. doi: 10.1016/j.anndiagpath.2024.152327. Epub 2024 May 11.
6
Accuracy of blood-based biomarkers for staging liver fibrosis in chronic liver disease: A systematic review supporting the AASLD Practice Guideline.用于慢性肝病肝纤维化分期的血液生物标志物准确性:支持美国肝病研究学会实践指南的系统评价
Hepatology. 2025 Jan 1;81(1):358-379. doi: 10.1097/HEP.0000000000000842. Epub 2024 Mar 15.
7
Guidelines for best practices in monitoring established coeliac disease in adult patients.成人患者中已确诊乳糜泻监测的最佳实践指南。
Nat Rev Gastroenterol Hepatol. 2024 Mar;21(3):198-215. doi: 10.1038/s41575-023-00872-2. Epub 2023 Dec 18.
8
A multisociety Delphi consensus statement on new fatty liver disease nomenclature.多学会专家共识:新脂肪性肝病命名。
Ann Hepatol. 2024 Jan-Feb;29(1):101133. doi: 10.1016/j.aohep.2023.101133. Epub 2023 Jun 24.
9
Transplantation for Primary Sclerosing Cholangitis: Outcomes and Recurrence.原发性硬化性胆管炎的肝移植:结局与复发
J Clin Med. 2023 May 11;12(10):3405. doi: 10.3390/jcm12103405.
10
Gut-liver axis: barriers and functional circuits.肠-肝轴:屏障和功能回路。
Nat Rev Gastroenterol Hepatol. 2023 Jul;20(7):447-461. doi: 10.1038/s41575-023-00771-6. Epub 2023 Apr 21.